Overview

The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
0
Participant gender:
All
Summary
Although the incidence of Hepatitis B has been decreased a lot recently years, there are still quite a few chronic hepatitis B patients in China. The anti-virus drugs of western medicine such as Entecavir and Tenofovir have been proved effective on decreasing the serum hepatitis B virus (HBV) level, on the other hand, Chinese materia medica showed effective on TCM syndromes of chronic hepatitis B (CHB) such as hypochondriac pain, jaundice and abdominal mass. Besides, the hepatic fibrosis could be delayed after the appropriate treatment of TCM. This study is a multicenter, randomized, open label, parallel group clinical trial to evaluate the efficacy of two different traditional Chinese medicine (TCM) herbal treatment on chronic hepatitis B.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xi'an Traditional Medicine Hospital
Treatments:
Entecavir
Liver Extracts
Tenofovir
Criteria
Inclusion Criteria:

- 18<=age at treatment<=65 years old

- Was diagnosed as chronic hepatitis B (ICD10:K73.901) and one of the following Chinese
syndromes: hypochondriac pain (TCD:BNG010), jaundice(TCD:BNG020) or abdominal mass
(TCD:BNG040).

Exclusion Criteria:

- Combined with other virus hepatitis or alcoholic hepatitis

- Combined with autoimmune disease

- Combined with liver cancer or cirrhosis

- Combined with severe hepatitis with or without complications

- Combined with unstable cardio-cerebrovascular disease

- Combined with severe lung, kidney, endocrine system, nervous system and hematological
system diseases

- Combined with Tuberculosis

- Chronic hepatitis patients with ongoing INF treatment

- Woman with pregnancy or breasting feeding

- Mental disorder and can not express self clearly

- Cannot speak Chinese

- Allergic constitution or allergy to multiple drugs

- Refuse to enroll into the study